TABLE 2.
Characteristics of study participants at baseline1
| Blueberry (n = 26) | Placebo (n = 26) | |||||
|---|---|---|---|---|---|---|
| Variable | Baseline | 4 wk | 8 wk | Baseline | 4 wk | 8 wk |
| Age, y | 67.1 ± 1.1 | – | – | 66.7 ± 1.1 | – | – |
| Height, cm | 173.6 ± 1.3 | – | – | 174.3 ± 1.3 | – | – |
| Weight, kg | 102.7 ± 1.1 | 102.5 ± 0.4 | 102.4 ± 0.4 | 102.4 ± 1.4 | 102.1 ± 0.4 | 102.4 ± 0.4 |
| BMI, kg/m2 | 34.2 ± 0.7 | 34.1 ± 0.1 | 34.0 ± 0.1 | 34.0 ± 0.9 | 33.8 ± 0.1 | 33.7 ± 0.1 |
| Waist circumference, cm | 116.4 ± 1.0 | 117.4 ± 0.5 | 116.8 ± 0.5 | 116.4 ± 1.0 | 116.1 ± 0.5 | 116.4 ± 0.5 |
| Race | ||||||
| White, alone | 25 (96) | 24 (92) | ||||
| Black or African American, alone | 1 (4) | 2 (8) | ||||
| Comorbidities | ||||||
| Hypertension | 24 (92) | 21 (81) | ||||
| Coronary heart disease | 19 (73) | 20 (77) | ||||
| Dyslipidemia | 17 (65) | 23 (88) | ||||
| Noninsulin diabetes medication users | 26 (100) | 26 (100) | ||||
| Biguanides | 20 (77) | 21 (80) | ||||
| Sulfonylureas | 5 (19) | 3 (12) | ||||
| Thiazolidinediones | 0 (0) | 1 (4) | ||||
| Dipeptidyl peptidase-4 inhibitors | 1 (4) | 1 (4) | ||||
| Antihypertensive medication users | 24 (92) | 21 (81) | ||||
| Angiotensin1 receptor blockers | 4 (16) | 5 (23) | ||||
| β-receptor blockers | 3 (13) | 1 (5) | ||||
| Angiotensin-converting enzyme inhibitors | 10 (42) | 9 (43) | ||||
| Calcium-channel blockers | 1 (4) | 1 (5) | ||||
| Diuretics | 6 (25) | 5 (24) | ||||
| Lipid-lowering medication users | 17 (65) | 23 (88) | ||||
| HMG-CoA reductase inhibitors | 17 (65) | 23 (88) | ||||
| Three-day food record dietary intake at baseline | ||||||
| Energy, kcal/d | 1824 ± 99 | 1840 ± 183 | ||||
| Carbohydrate, g | 186 ± 10 | 191 ± 18 | ||||
| Protein, g | 81 ± 5 | 80 ± 6 | ||||
| Fat, g | 84 ± 6 | 84 ± 11 | ||||
| Fiber, g | 15 ± 1 | 15 ± 2 | ||||
1
All values are means ± SEs or n (%). Statistical comparisons were made by ANOVA. No differences between groups were observed at baseline. HMG-CoA, 3-hydroxy-3-methyl-glutaryl-CoA.